扩展抗原谱系揭示复发性、隐蔽性及造血限制性HLA I类次要组织相容性抗原
该研究从39例移植患者中分离T细胞克隆,针对1000基因组计划中191株EB病毒转化B细胞系进行全基因组关联筛选,新发现81个次要组织相容性抗原(MiHAs),使抗原谱系增至159个,并发现其中四分之一为隐蔽性抗原,11个为造血限制性抗原。
要点
- 新发现81个MiHAs,使HLA-I限制性MiHAs谱系增至159个。
- 约四分之一MiHAs为隐蔽性抗原,由非常规开放阅读框翻译。
- 鉴定11个造血限制性MiHAs,可作为免疫治疗潜在靶点。
核心结论
- 扩展了HLA-I限制性MiHAs谱系,鉴定出复发性、隐蔽性及造血限制性抗原,对预测、追踪或调控alloSCT后免疫反应以改善临床结局具有基础意义。
研究设计与样本
- 从39例移植患者中分离T细胞克隆,针对1000基因组计划中191株EB病毒转化B细胞系进行全基因组关联筛选。
主要发现
- 新发现81个MiHAs,使抗原谱系增至159个,并证明尽管患者与供者间存在许多遗传差异,多个患者常靶向相同的MiHAs。
- 约四分之一抗原为隐蔽性抗原,由非常规开放阅读框(如长非编码RNA)翻译而来。
- 利用单细胞RNA-seq数据分析MiHA编码基因的组织表达,鉴定出11个新的造血限制性MiHAs作为免疫治疗潜在靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells recognizing polymorphic peptides, designated minor histocompatibility antigens (MiHAs), that are presented by HLA on malignant patient cells. However, T cells often target MiHAs on healthy nonhematopoietic tissues of patients, thereby inducing side effects known as graft-versus-host disease. Here, we aimed to identify the dominant repertoire of HLA-I-restricted MiHAs to enable strategies to predict, monitor or modulate immune responses after alloSCT. To systematically identify novel MiHAs by genome-wide association screening, T-cell clones were isolated from 39 transplanted patients and tested for reactivity against 191 Epstein-Barr virus transformed B cell lines of the 1000 Genomes Project. By discovering 81 new MiHAs, we more than doubled the antigen repertoire to 159 MiHAs and demonstrated that, despite many genetic differences between patients and donors, often the same MiHAs are targeted in multiple patients. Furthermore, we showed that one quarter of the antigens are cryptic, that is translated from unconventional open reading frames, for example long noncoding RNAs, showing that these antigen types are relevant targets in natural immune responses. Finally, using single cell RNA-seq data, we analyzed tissue expression of MiHA-encoding genes to explore their potential role in clinical outcome, and characterized 11 new hematopoietic-restricted MiHAs as potential targets for immunotherapy. In conclusion, we expanded the repertoire of HLA-I-restricted MiHAs and identified recurrent, cryptic and hematopoietic-restricted antigens, which are fundamental to predict, follow or manipulate immune responses to improve clinical outcome after alloSCT.
引用
- Fuchs KJ, van de Meent M, Honders MW, et al. Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens. Blood. 2024. PMID: 38427583. doi:10.1182/blood.2023022343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。